PURPOSE: To better define determinants of survival and optimal management strategies for @entity1 with @entity43 and brain metastases. METHODS: A review of literature using Medline identified 15 case series of @entity43 @entity1 with brain metastases (OBM). Each article was abstracted for survival data, and in all cases, the intervals between @entity43 diagnosis and brain @entity3 identification, and between brain @entity3 identification and last follow-up were recorded. Cases were categorized by @entity1 characteristics and treatment modality for brain metastases. Estimated survival probabilities were plotted using the Kaplan-Meier method with differences between subgroups analyzed by the log-rank test. Cox proportional hazards model was used to identify independent prognostic factors age, number of @entity3 , and treatment modality associated with survival. RESULTS: The median interval from @entity43 diagnosis to brain @entity3 in 104 identified @entity1 was 19.5 months. Brain @entity3 was single in 43%, multiple in 41%, and not reported in 16% of cases. About 81.7% of @entity1 were treated for their brain metastases using external radiation therapy (XRT), chemotherapy, and surgery. XRT was utilized in 76% of 104 @entity1 and in 93% of treated @entity1 . The most commonly used modalities were XRT alone (40%) and craniotomy and XRT (17%). The @entity1349 ( @entity1349 ) for all @entity1 regardless of treatment type was 6 months. @entity1 who received any treatment lived longer than those not receiving surgery/chemotherapy/XRT ( @entity1349 ; 7 months vs. 2 months, P = 0.0001). @entity1 with single brain @entity3 had a longer @entity1349 (21 months vs. 6 months, P = 0.049) when treated with craniotomy plus radiation and/or chemotherapy compared to treatment regimens that excluded craniotomy. In a multivariate analysis, only treatment type was significant in predicting survival. CONCLUSION: OBM portends a poor prognosis, however, long-term survival is possible. @entity1 appear to benefit from therapy, especially selected groups of OBM @entity1 with single brain @entity3 treated with radiation therapy and surgery.

XXXX metastatic to the brain: what is the optimal management?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['median survival', 'MS']
@entity43 :: (MESH:D010051,Disease) :: ['Ovarian cancer']
